CClinicalTrials.gg
CompletedNCT04376775COWAITUpdated Jun 7, 2021

Assessment of the Impact of COVID-19 on Transplant Patients and on Patients Awaiting Transplantation

An observational study in Transplantation, sponsored by University Hospital, Bordeaux. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-07.

Sponsored by University Hospital, Bordeaux · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,602
Ages
18 Years and older
Sex
All
01

Study summary

To provide optimal care to patients and to maintain long-term institutional viability, Transplant Centres (TC) must have an awareness of their patients' health status, their health care needs and priorities, as well as their access to information and health care. For example, it is critical that TCs understand whether their patients are medically suitable for transplant, whether transplantation remains a priority for their patients, how best to communicate with their patients, and whether their patients have sufficient access to medications and health care to undergo transplant safely. The COVID-19 pandemic has had a tremendous impact on people and institutions around the country in a short period of time. At this time, little is known regarding its impact on the transplant community specifically. For example, it has been reported that around 8 million French applied for partial unemployment benefit over the past month, but it is not known if this has affected transplant patients. It has been reported that people with significant chronic medical conditions and those with compromised immune systems may be at increased risk of dying from the COVID-19, but it is not known if this has affected patients' interest in receiving transplants at this time. The "Société Francophone de Transplantation (SFT)" published recommendations at the beginning of the pandemic in order to limit the rate of infection in these high-risk population. The purpose of this study is to better understand the impact of COVID-19 on patients on the waiting list and transplant patients. Further, a better understand on how patients have received information about this pandemic and how best to communicate with them.

Read the detailed description

Transplant Centres (TCs) serve a unique patient population, those with end-organ disease who are either waiting for, or who have received, a solid-organ transplant. For transplant candidates, TCs help weigh the threat of their current condition against the intended benefits and associated risks of transplantation, which include major-surgery and chronic immune suppression (IS). For transplant recipients, TCs help manage the life-long risks associated with IS, including infection and malignancy, and facilitate access to appropriate health care over time.

To provide optimal care to patients and to maintain long-term institutional viability, TCs must have an awareness of their patients' health status, their health care needs and priorities, as well as their access to information and health care. For example, it is critical that TCs understand whether their patients are medically suitable for transplant, whether transplantation remains a priority for their patients, how best to communicate with their patients, and whether their patients have sufficient access to medications and health care to undergo transplant safely.

The COVID-19 pandemic has had a tremendous impact on people and institutions around the country in a short period of time. At this time, little is known regarding its impact on the transplant community specifically. For example, it has been reported that around 8 million French applied for partial unemployment benefit over the past month, but it is not known if this has affected transplant patients. It has been reported that people with significant chronic medical conditions and those with compromised immune systems may be at increased risk of dying from the COVID-19, but it is not known if this has affected patients' interest in receiving transplants at this time. The "Société Francophone de Transplantation (SFT)" published recommendations at the beginning of the pandemic in order to limit the rate of infection in these high-risk population. Briefly, these recommendations encompassed the following points: Not stopping immunosuppression, strict application of the social distancing, recommendation to stay and work at home, recommendation to limit the visits at the hospital. However, it is still unclear whether these recommendations were followed by the transplant recipients, and if this exceptional situation has affected their access to health care or needed medications.

The purpose of our study is to better understand the impact of COVID-19 on patients on the waiting list and transplant patients. Further, a better understand on how patients are receiving information about this pandemic and how best to communicate with them. The hypothesis is that peri-transplant patient groups may appropriately perceive themselves to be at high risk of infection and poor outcomes, and that this may influence their decisions around seeking medical care and willingness to undergo organ transplantation. Additionally, the investigator anticipate a wide range of needs and risks among patients, including their ability to isolate from potential infection, ability to access medications and medical care, and their ability to access information regarding COVID-19. Ultimately, the investigator plan to use the information collected from patients to improve patient education regarding COVID-19 and to inform centres' response to future epidemics and/or natural disasters that disrupt patient care. Until now, no systematic description of transplant patients' needs, priorities, behavior's, attitudes, or education has been done during this pandemic.

02

Conditions studied

  • Transplantation

Browse trials for

Keywords

  • Waiting list
  • Transplantation
  • Covid-19
03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's enrollment of 3,602 is above the median of 261 across 3,136 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

University Hospital, Bordeaux is the lead sponsor of 783 studies on the registry; 188 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients registered on the French waiting list for a transplant and patients transplanted with a functional graft.

Inclusion criteria

  • Over 18 years of age
  • Patients currently (at the time of survey) on a French transplant waiting list.
  • Patients transplanted with a functional graft.

Exclusion criteria

Exclusion Criteria:

  • Under 18 years of age,
  • Patients under protective measures or deprived of their liberty:

pregnant or breastfeeding woman, under guardianship, under curatorship, safeguard of justice, incarcerated.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,602 participants (actual)
Patient registry
No

Groups and cohorts

  • Transplant patient

    This study will involve all the transplant centres in France. The investigator will use patient-completed surveys for all participants. Wait Listed Transplant Candidates and Transplant Recipients (liver, kidney, pancreas, heart, lung) will be contacted by the all French transplant centres and patient's associations.

    Other: Transplant patient

Interventions

  • OtherTransplant patient

    Surveys will be distributed via an email sent by transplant centres or patient's associations. A link to a secure survey platform will be given. A questionnaire will completed by patients. Patients, who agreed to fill the survey, will be offered the possibility to be contacted for a second survey over a 6 months period.

06

What researchers measure

Primary outcomes

  1. Compliance precautions with COVID-19

    The compliance will be assessed by the questionnaire created for the study. The questionnaire has 38 questions with multiple choice for each question.

    Time frame: In a maximum of 6 months after inclusion

Secondary outcomes

  1. Clinical impact of COVID-19

    The clinical impact will be assessed by the questionnaire created for the study. The questionnaire has 38 questions with multiple choice for each question.

    Time frame: In a maximum of 6 months after inclusion

07

Study locations

1 site
  • Hopital Pellegrin
    Bordeaux, 33000, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04376775
Lead sponsor
University Hospital, Bordeaux
Collaborators
Société Francophone de Transplantation
Responsible party
Sponsor
First posted
May 6, 2020
Start date
May 11, 2020
Primary completion
May 11, 2020
Completion
May 11, 2020
Last update
Jun 7, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion